Bill Gates, co-chair of the Bill & Melinda Gates Foundation, called on government leaders to increase their investments in vaccines and to hold themselves accountable for extending the benefits of vaccines to every child.
In a keynote address at the 64th World Health Assembly, an annual gathering of health ministers and global health leaders, Gates laid out his vision for the impact that broadening access to vaccines can have on the world. “Strong immunization systems will put an end to polio and help us reach all children with five to six new vaccines,” Gates said. “We can save four million lives by 2015, and 10 million lives by 2020.”
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/gatesfoundation/49363/
CVS/pharmacy, the nation’s leading retail pharmacy, and MinuteClinic, the largest retail health care clinic provider in the U.S., today announced that flu vaccinations are now available at all of its locations nationwide. CVS/pharmacy has more than 7,000 locations and MinuteClinic has more than 500 locations inside select CVS/pharmacy stores.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cvspharmacy/45561/
Today the Confederation of Meningitis Organisations (CoMO) is urging people all over the world to “Join Hands Against Meningitis” in an effort to reduce the global impact of the disease. The call-to-action encourages individuals, families and communities to learn the signs and symptoms of meningitis, the importance of urgent treatment of the disease, and that prevention is available through vaccination against some forms of meningitis.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55808-world-meningitis-day-join-the-fight-to-stop-meningitis
March of Dimes, the leading non-profit organization for maternal and infant health, will celebrate its 75th anniversary in 2013 and its ongoing work to help all babies get a healthy start in life. About 4 million babies are born in the United States each year, and the March of Dimes has helped each and every one through research, education, vaccines, and breakthroughs.
To view Multimedia News Release, go to http://www.multivu.com/players/English/59684-march-of-dimes-75th-anniversary/
Today, MedImmune Specialty Care division of AstraZeneca (MedImmune Specialty Care) announced it has joined with actress Tia Mowry to raise awareness about the importance of an annual flu vaccination. To kick-off the campaign, MedImmune Specialty Care and Mowry unveiled an online video, “I Insist!” (www.YouTube.com/InsistOnTheMist), which uses comedy to educate busy families about the importance of living a healthy lifestyle and making flu vaccination a priority. For Mowry, this includes vaccination with FluMistQuadrivalent, the first and only FDA-approved needle-free flu vaccine for eligible persons 2-49 years old. FluMist Quadrivalent is administered as a gentle mist sprayed into the nose, where the influenza virus usually enters the body.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63079-medimmune-specialty-care-tia-mowry-flumist-quadrivalent-encourage-flu-shot
Building upon its efforts to provide greater access to vaccines and other health care services for populations in need, Walgreens (NYSE: WAG) (Nasdaq: WAG) is partnering with the United Nations Foundation this flu season, to help provide up to 3 million life-saving vaccines to children in developing countries through a donation to the Foundation’s Shot@Life campaign.
To view Multimedia News Release, go to http://www.multivu.com/players/English/62923-walgreens-flu-season2013
Many parents had their children vaccinated when they were younger, but some vaccines are also recommended for older children. Beyond focusing on school supplies, extracurricular activities, and fall schedules, the back-to-school time is a good opportunity for parents to talk with their health care professional about vaccines that may be recommended for their preteen or teen.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62743-merck-webmd-healthywomen-back-to-school-means-back-to-vaccines
Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65511-issels-integrative-immunotherapy-non-toxic-treatment-lung-cancer
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the initiation of its Phase III clinical program called Cdiffense to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection (CDI). Clostridium difficile (C. diff) is a potentially life-threatening, spore-forming bacterium that causes intestinal disease. The risk of C. diff increases with age, antibiotic treatment and time spent in hospitals or nursing homes, where multiple cases can lead to outbreaks. The investigational vaccine is designed to help protect at-risk individuals from C. diff, which is emerging as a leading cause of life-threatening, healthcare-associated infections (HAIs) worldwide.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62652-sanofi-pasteur-initiates-phase-iii-study-of-investigational-vaccine
More than 300 global leaders, health and development experts, vaccinators, celebrities, philanthropists, and business leaders will gather tomorrow in Abu Dhabi in the first Global Vaccine Summit to endorse the critical role that vaccines and immunization play in giving children a healthy start to life. Despite tremendous progress, one child still dies every 20 seconds from preventable diseases like pneumonia, rotavirus, measles, and meningitis.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61396-bill-and-melinda-gates-foundation-first-global-vaccine-summit
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of Fluzone® (Influenza Vaccine) for the 2016-2017 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA) for shipment. This represents the first of more than 65 million total doses of seasonal influenza vaccine manufactured by Sanofi Pasteur that will be delivered to U.S. health care providers and pharmacies beginning in July and continuing throughout the remainder of the year. Sanofi Pasteur plans to increase its supply to respond to the shifting pediatric public health needs.
Seasonal influenza activity typically occurs between October and May and peaks between December and February. However, influenza activity peaked noticeably late last season occurring in early March 2016.1 Influenza seasons are always unpredictable as new influenza strains emerge and strain activity fluctuates throughout the year, making timely vaccination even more important to help protect against the virus, especially for seniors, young children and infants six months of age and older.
To view the multimedia release go to:
http://www.multivu.com/players/English/7842051-sanofi-pasteur-influenza-vaccine/
Seqirus is now shipping its complete portfolio of seasonal influenza vaccines to customers in the US market for the 2016-2017 season. Seqirus is the only influenza vaccine manufacturer to produce influenza vaccines using both egg-based and cell culture technologies, and the only provider in the US that offers both quadrivalent and trivalent influenza vaccines, as well as the only adjuvanted seasonal influenza vaccine.
Seqirus is now shipping to the US all influenza vaccines in its portfolio, including Fluad™ (Influenza Vaccine, Adjuvanted), Flucelvax Quadrivalent™ (Influenza Vaccine), Afluria® (Influenza Vaccine), and Fluvirin® (Influenza Virus Vaccine) in advance of the peak of influenza season.
“Seqirus is proud to be a major contributor to the prevention and control of influenza by offering healthcare providers and pharmacists with a range of clinically proven, innovative vaccination options that help protect people against the debilitating effects of the disease,” said Brent MacGregor, Senior Vice President, Commercial Operations. “We are committed to being an early and reliable supplier of our influenza vaccines to help ensure that appropriate patients have plenty of time to get their annual immunization.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7902351-seqirus-franchise-shipment/
